Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $511,400.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the completion of the sale, the director now owns 157,557 shares of the company’s stock, valued at $16,114,929.96. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Blueprint Medicines Stock Up 2.3 %

BPMC stock traded up $2.33 during trading on Wednesday, hitting $104.89. 1,114,529 shares of the company’s stock were exchanged, compared to its average volume of 999,285. The business has a 50-day moving average price of $93.75 and a two-hundred day moving average price of $95.29. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -49.71 and a beta of 0.61. Blueprint Medicines Co. has a 52-week low of $72.24 and a 52-week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s revenue was up 126.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.20) EPS. As a group, equities research analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BPMC. Needham & Company LLC reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Monday. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price objective for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.72.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $32,000. Covestor Ltd lifted its stake in Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Blueprint Medicines in the third quarter valued at approximately $108,000. Values First Advisors Inc. acquired a new stake in shares of Blueprint Medicines in the third quarter valued at approximately $122,000. Finally, CWM LLC grew its position in shares of Blueprint Medicines by 69.2% during the third quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 765 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.